Ligand Pharmaceuticals, Inc. (LGND) Tops Q2 EPS by 10c; Boosts FY14 Outlook

Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q2 EPS of $0.24, $0.10 better than the analyst estimate of $0.14. Revenue for the quarter came in at $10.6 million versus the consensus estimate of $9.73 million.

Ligand Pharmaceuticals, Inc. sees Q3 2014 EPS of $0.26-$0.29, versus the consensus of $0.4. Ligand Pharmaceuticals, Inc. sees Q3 2014 revenue of $13-14 million, versus the consensus of $16.6 million.

Ligand Pharmaceuticals, Inc. sees FY2014 EPS of $1.50-$1.55, versus prior guidance of $1.4-$1.45 and the consensus of $1.44. Ligand Pharmaceuticals, Inc. sees FY2014 revenue of $64-66 million, versus prior guidance of $64-66 million and the consensus of $62.9 million.

For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.

You May Also Be Interested In

• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Lennar Corp. (LEN) Misses Q2 EPS by 1c
• Sharon AI secures six-year compute deal with NVIDIA for Australia deployment